Affordable Access

Publisher Website

Bioprocess development for cord blood mesenchymal stromal cells on microcarriers in Vertical-Wheel bioreactors.

Authors
  • Roberts, Erin L1, 2
  • Lepage, Sarah I M3
  • Koch, Thomas G3
  • Kallos, Michael S1, 2
  • 1 Pharmaceutical Production Research Facility, Schulich School of Engineering, University of Calgary, Calgary, Alberta, Canada. , (Canada)
  • 2 Department of Biomedical Engineering, Schulich School of Engineering, University of Calgary, Calgary, Alberta, Canada. , (Canada)
  • 3 Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada. , (Canada)
Type
Published Article
Journal
Biotechnology and Bioengineering
Publisher
Wiley (John Wiley & Sons)
Publication Date
Jan 01, 2024
Volume
121
Issue
1
Pages
192–205
Identifiers
DOI: 10.1002/bit.28557
PMID: 37772415
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Equine mesenchymal stromal cells (MSCs) have been found to be beneficial for the treatment of many ailments, including orthopedic injuries, due to their superior differentiation potential and immunomodulating properties. Cell therapies require large cell numbers, which are not efficiently generated using conventional static expansion methods. Expansion of equine cord blood-derived MSCs (eCB-MSCs) in bioreactors, using microcarriers as an attachment surface, has the potential to generate large numbers of cells with increased reproducibility and homogeneity compared with static T-flask expansion. This study investigated the development of an expansion process using Vertical-Wheel (VW) bioreactors, a single-use bioreactor technology that incorporates a wheel instead of an impeller. Initially, microcarriers were screened at small scale to assess eCB-MSC attachment and growth and then in bioreactors to assess cell expansion and harvesting. The effect of different donors, serial passaging, and batch versus fed batch were all examined in 0.1 L VW bioreactors. The use of VW bioreactors with an appropriate microcarrier was shown to be able to produce cell densities of up to 1E6 cells/mL, while maintaining cell phenotype and functionality, thus demonstrating great potential for the use of these bioreactors to produce large cell numbers for cell therapies. © 2023 The Authors. Biotechnology and Bioengineering published by Wiley Periodicals LLC.

Report this publication

Statistics

Seen <100 times